Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis

Abstract Lung adenocarcinoma (LUAD) is a major contributor to cancer-related deaths, distinguished by its pronounced tumor heterogeneity and persistent challenges in overcoming drug resistance. In this study, we utilized single-cell RNA sequencing (scRNA-seq) to dissect the roles of programmed cell...

Full description

Saved in:
Bibliographic Details
Main Authors: Long Li, Shancheng He
Format: Article
Language:English
Published: Springer 2024-12-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-024-01736-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846101072226025472
author Long Li
Shancheng He
author_facet Long Li
Shancheng He
author_sort Long Li
collection DOAJ
description Abstract Lung adenocarcinoma (LUAD) is a major contributor to cancer-related deaths, distinguished by its pronounced tumor heterogeneity and persistent challenges in overcoming drug resistance. In this study, we utilized single-cell RNA sequencing (scRNA-seq) to dissect the roles of programmed cell death (PCD) pathways, including apoptosis, necroptosis, pyroptosis, and ferroptosis, in shaping LUAD heterogeneity, immune infiltration, and prognosis. Among these, ferroptosis and pyroptosis were most significantly associated with favorable survival outcomes, highlighting their potential roles in enhancing anti-tumor immunity. Distinct PCD-related LUAD subtypes were identified, characterized by differential pathway activation and immune cell composition. Subtypes enriched with cytotoxic lymphocytes and dendritic cells demonstrated improved survival outcomes and increased potential responsiveness to immunotherapy. Drug sensitivity analysis revealed that these subtypes exhibited heightened sensitivity to targeted therapies and immune checkpoint inhibitors, suggesting opportunities for personalized treatment strategies. Our findings emphasize the interplay between PCD pathways and the tumor microenvironment, providing insights into the mechanisms underlying tumor drug resistance and immune evasion. By linking molecular and immune features to clinical outcomes, this study highlights the potential of targeting PCD pathways to enhance therapeutic efficacy and overcome resistance in LUAD. These results contribute to a growing framework for developing precise and adaptable cancer therapies tailored to specific tumor characteristics.
format Article
id doaj-art-b61f625fb13d43ed825e7b723f784b2a
institution Kabale University
issn 2730-6011
language English
publishDate 2024-12-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-b61f625fb13d43ed825e7b723f784b2a2024-12-29T12:37:37ZengSpringerDiscover Oncology2730-60112024-12-0115111310.1007/s12672-024-01736-0Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysisLong Li0Shancheng He1Department of Critical Care Medicine, The Fifth People’s Hospital of Ganzhou CityDepartment of Critical Care Medicine, The Fifth People’s Hospital of Ganzhou CityAbstract Lung adenocarcinoma (LUAD) is a major contributor to cancer-related deaths, distinguished by its pronounced tumor heterogeneity and persistent challenges in overcoming drug resistance. In this study, we utilized single-cell RNA sequencing (scRNA-seq) to dissect the roles of programmed cell death (PCD) pathways, including apoptosis, necroptosis, pyroptosis, and ferroptosis, in shaping LUAD heterogeneity, immune infiltration, and prognosis. Among these, ferroptosis and pyroptosis were most significantly associated with favorable survival outcomes, highlighting their potential roles in enhancing anti-tumor immunity. Distinct PCD-related LUAD subtypes were identified, characterized by differential pathway activation and immune cell composition. Subtypes enriched with cytotoxic lymphocytes and dendritic cells demonstrated improved survival outcomes and increased potential responsiveness to immunotherapy. Drug sensitivity analysis revealed that these subtypes exhibited heightened sensitivity to targeted therapies and immune checkpoint inhibitors, suggesting opportunities for personalized treatment strategies. Our findings emphasize the interplay between PCD pathways and the tumor microenvironment, providing insights into the mechanisms underlying tumor drug resistance and immune evasion. By linking molecular and immune features to clinical outcomes, this study highlights the potential of targeting PCD pathways to enhance therapeutic efficacy and overcome resistance in LUAD. These results contribute to a growing framework for developing precise and adaptable cancer therapies tailored to specific tumor characteristics.https://doi.org/10.1007/s12672-024-01736-0Lung adenocarcinomaProgrammed cell deathSingle-cell RNA sequencingTumor heterogeneityDrug resistanceImmune infiltration
spellingShingle Long Li
Shancheng He
Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis
Discover Oncology
Lung adenocarcinoma
Programmed cell death
Single-cell RNA sequencing
Tumor heterogeneity
Drug resistance
Immune infiltration
title Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis
title_full Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis
title_fullStr Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis
title_full_unstemmed Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis
title_short Programmed cell death pathways in lung adenocarcinoma: illuminating tumor drug resistance and therapeutic opportunities through single-cell analysis
title_sort programmed cell death pathways in lung adenocarcinoma illuminating tumor drug resistance and therapeutic opportunities through single cell analysis
topic Lung adenocarcinoma
Programmed cell death
Single-cell RNA sequencing
Tumor heterogeneity
Drug resistance
Immune infiltration
url https://doi.org/10.1007/s12672-024-01736-0
work_keys_str_mv AT longli programmedcelldeathpathwaysinlungadenocarcinomailluminatingtumordrugresistanceandtherapeuticopportunitiesthroughsinglecellanalysis
AT shanchenghe programmedcelldeathpathwaysinlungadenocarcinomailluminatingtumordrugresistanceandtherapeuticopportunitiesthroughsinglecellanalysis